Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial

Punzi, Henry; Lewin, Andrew; Lukić, Tamara; Goodin, Thomas; Chen, Wei

doi:10.1177/1753944710387629

Cited by 15 publications

(10 citation statements)

References 29 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the nonobese placebo group had a higher percentage of Hispanics than the other nonobese pooled treatment groups. A greater placebo response has been observed in Hispanic participants in phase 3 nebivolol and nebivolol/valsartan clinical trials, thus the placebo response in this study may be overestimated. Despite this aberration, the nebivolol/valsartan SPC was still more effective than placebo in this group .…”

Section: Study Limitationsmentioning

confidence: 60%

Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension

Mende

Giles

Bharucha

et al. 2017

J of Clinical Hypertension

View full text Add to dashboard Cite

Antihypertensive efficacy of single‐pill combinations (SPCs) consisting of a β1‐selective adrenergic blocker with vasodilatory properties via β3‐agonism (nebivolol) and an angiotensin II receptor blocker (valsartan) was demonstrated in an 8‐week phase 3 trial (NCT01508026). In this post hoc analysis, seated blood pressure, heart rate, 24‐hour ambulatory blood pressure monitoring, plasma aldosterone, estimated glomerular filtration rate, and safety measures were assessed in obese (body mass index >32 kg/m2; n=1823) and nonobese (body mass index <27 kg/m2; n=847) adults with hypertension (stage I or II) treated with nebivolol‐valsartan SPCs, nebivolol or valsartan monotherapy, or placebo. At week 8, reductions from baseline in blood pressure and ambulatory blood pressure monitoring were greater with SPCs and most nebivolol and valsartan monotherapy doses vs placebo regardless of obesity status. Aldosterone declined with all active treatments and estimated glomerular filtration rate remained steady. The nebivolol‐valsartan 5/80 mg/d SPC was efficacious regardless of degree of obesity.

show abstract

Section: Study Limitationsmentioning

confidence: 60%

Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension

Mende

Giles

Bharucha

et al. 2017

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…[12] Results from the small number of antihypertensive trials that enrolled significant numbers of Hispanic patients are also limited because ethnicity and/or race were usually self-reported,[40–42] which may have affected the uniformity of data capture, and in most cases no distinctions were made between Hispanic Whites and Hispanic Blacks.…”

Section: Efficacy Of Antihypertensive Agents In Hispanics: Review mentioning

confidence: 99%

“…Analysis of these articles identified 17[30,31,40–54] publications involving 15 different studies that specifically reported on the efficacy and safety of antihypertensive agents in Hispanic patients. Additional data from the INVEST study (table I provides full names of trial acronyms used in this article) was also included from a publication not identified in this search.…”

Section: Efficacy Of Antihypertensive Agents In Hispanics: Review mentioning

confidence: 99%

“…The main results from all identified articles (n = 18) and abstracts (n = 4) presenting data from 19 studies are summarized in table II. [29–31,40–58]

Table IFull trial names of study acronyms used in this article

Table IIStudies reporting on the efficacy of antihypertensive agents in the Hispanic population (PubMed findings)…”

Section: Efficacy Of Antihypertensive Agents In Hispanics: Review mentioning

confidence: 99%

“…[40–58] In general, all of the different classes of antihypertensive drugs substantially reduced BP in Hispanic patients, and greater BP reductions were observed with combination therapy than with monotherapy. In most cases, a RAAS inhibitor (ACE inhibitor, angiotensin II receptor blocker [ARB], or DRI) was used, either alone or in combination with another antihypertensive agent.…”

Section: Efficacy Of Antihypertensive Agents In Hispanics: Review mentioning

confidence: 99%

See 2 more Smart Citations

Epidemiology and Management of Hypertension in the Hispanic Population

Guzmán

2012

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

Hispanics are the fastest growing ethnic minority in the USA. Among Hispanics, lack of hypertension awareness and lack of effective blood pressure (BP) control are problematic, as are higher incidence rates of hypertension-related co-morbidities compared with non-Hispanic populations. Moreover, there are currently no hypertension treatment guidelines that address the unique characteristics of this ethnic group. This article discusses ethnic differences in hypertension and cardiovascular risk factors and reviews the literature on the efficacy of antihypertensive agents in Hispanic patients, with a focus on the role of renin-angiotensinaldosterone system (RAAS) inhibition in the management of hypertension in these patients. Hypertension in Hispanic patients can be challenging to manage, in part because this population has a higher prevalence of obesity, diabetes, and metabolic syndrome compared with non-Hispanic whites. The presence of these comorbidities suggests that RAAS-inhibitor-based therapies may be particularly beneficial in this population. However, few studies have evaluated the efficacy of antihypertensive treatments in Hispanic patients. Two outcomes studies in hypertensive patients have shown the benefits of treating Hispanic patients with antihypertensive therapy and included RAAS inhibitors as part of the treatment regimen. In addition, BP-lowering trials have shown the antihypertensive efficacy of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors, although data on the latter are more limited. Additional studies are needed to more thoroughly evaluate the effects of RAAS inhibitors (and other drug classes) on outcomes and BP lowering in the Hispanic hypertensive population.

show abstract

First-line drugs for hypertension

Wright

Musini

Gill

2018

Cochrane Database of Systematic Reviews

227

View full text Add to dashboard Cite

Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial

Abstract: In Hispanics with stage I-II hypertension, 8-week nebivolol monotherapy resulted in significant reductions in blood pressure. The safety and tolerability profile of nebivolol was similar to that of placebo.

Cited by 15 publications

References 29 publications

Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension

Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension

Epidemiology and Management of Hypertension in the Hispanic Population

First-line drugs for hypertension

Contact Info

Product

Resources

About